Topic: mergers and acquisitions
There’s been a deal at the J.P. Morgan Healthcare Conference, but probably not with the largest names and certainly not big bucks.
The takeover, which values Dermira at just a whisker above its closing price yesterday, comes months after the biotech posted phase 2b data.
Midsized European drug discovery CRO MercachemSyncom has bought Netherlands-based Alcami’s Weert, Netherlands site.
Contract research organization Veristat has snapped up fellow CRO The Clinical Trial Company as it looks to boost its presence in Europe.
The deal will see Denmark’s Galecto incorporate in the U.S. and add a clinical-phase treatment for idiopathic pulmonary fibrosis to its pipeline.
Illumina and PacBio called off their $1.2 billion merger, which has been in the works for over a year, after the FTC described it as "monopolist."
After fielding multiple takeover offers over the past month, Qiagen has instead decided to go it alone—and investors are less than pleased.
J&J is moving to fully take over its robotic surgery venture with Google’s sibling company, Verily, by acquiring the remaining stake of Verb Surgical.
The FTC has moved to block Illumina’s $1.2 billion takeover of Pacific Biosciences, saying the merger would substantially harm competition.
Charles River Labs is stumping up $380 million in cash to buy out cell therapy biomaterials producer HemaCare.
